A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
During this fireside we welcome Modular Medical. Modular Medical, Inc. (NASDAQ:MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to...
SAN DIEGO, CA / September 30, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its...
Allowed claims cover major features of pumping mechanism in FDA-cleared MODD1 productSAN DIEGO, CA / September 18, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch...
-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024-Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for people who discontinue long-acting GLP-1 formulations-CEO to discuss...
Meet with Modular Medical CEO, Jeb BesserThere are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US.100% of patient population require daily insulin injection. Only 20% currently use an insulin pump.Obesity is linked to...
SAN DIEGO, CA / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay...
MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetesDesigned to be simpler and more affordable to expand access to diabetes technology for previously underserved communitiesCommercial availability expected in early 2025 SAN DIEGO, CA / September 4,...
The global diabetes care market, valued at $18.9 billion in 2023, is projected to reach $35.8 billion by 2028The insulin pump segment is expected to grow from $5.26 billion to $21.65 billion by 2032Discover how Modular Medical is accelerating the development of...
SAN DIEGO, CA / August 7, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch the next generation of easy-to-use, prescribe and live with affordable insulin pump technology,...
Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people who discontinue long-acting GLP-1 formulations SAN DIEGO, CA / July 15, 2024 / Modular Medical, Inc. (NASDAQ:MODD)...